Vilanterol, a novel inhaled long-acting β2 adrenoceptor agonist (LABA), demonstrates extensive first pass clearance to metabolites with negligible pharmacological activity in man Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
In vitro pharmacological profile of CHF 5407, a potent, long-acting and selective muscarinic M3 receptor antagonistSource: Eur Respir J 2007; 30: Suppl. 51, 25s Year: 2007
In vivo potent and long-lasting bronchodilator activity of muscarinic M3 receptor antagonist CHF5407Source: Eur Respir J 2007; 30: Suppl. 51, 26s Year: 2007
A novel dual-agonist challenge model in guinea pigs for assessment of individual and combined muscarinics antagonists and b2 adrenoceptor agonists bronchodilator efficacy Source: Annual Congress 2011 - Models of disease and drug actions Year: 2011
A novel lung pharmacokinetic model predicts lung exposure and supports dose selection for clinical study of AZD2115, a dual muscarinic receptor antagonist/beta2 adrenoceptor agonist (MABA) Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD Year: 2015
Bronchoprotective activity and safety evaluation of the novel antimuscarinic/ß2 agonist (MABA) CHF6366 in dogs Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017
Pharmacological characterization of CHF6162, a novel long acting inhaled corticosteroid for the treatment of asthma Source: International Congress 2017 – Novel mechanisms and treatments for asthma Year: 2017
Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation, in COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
Demonstration of dual pharmacology in vivo of PF-3429281: A novel inhaled dual antimuscarinic/β2 agonist Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators Year: 2010
Safety and toleration of pf-00610355, a novel inhaled long acting β2 adrenoreceptor agonist Source: Annual Congress 2009 - New bronchodilators Year: 2009
Anti-inflammatory and immunomodulatory potential of Cys LT1 receptor antagonists (LTRA) in steroid dependent persistent asthma Source: Eur Respir J 2005; 26: Suppl. 49, 136s Year: 2005
Pharmacokinetics of PF-00610355, a novel inhaled long-acting β2 -adrenoreceptor agonist Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Rate of onset of action of aclidinium bromide, a novel, long-acting, muscarinic antagonist Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Characterising the cardiovascular safety profile of inhaled muscarinic receptor antagonists Source: Eur Respir Monogr 2020; 88: 238-250 Year: 2020
An oral selective M3 cholinergic receptor antagonist in COPD Source: Eur Respir J 2006 Oct 01;28(4):772-780 Year: 2006
Metabolism of ASM-024, a novel nicotinic agonist being developed for the treatment of asthma Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
A dual-acting muscarinic antagonist, ß2 -agonist [MABA] molecule (GSK961081) improves lung function in COPD. A randomised trial Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012
In vitro pharmacological characterization of two novel dual-acting MABA compounds (LAS190792 and LAS191351)Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014
The dual PDE3/PDE4 phosphodiesterase inhibitor RPL554 produces more complete bronchodilator responses than the beta2-agonist salbutamol and the anti-muscarinic agent ipratropium bromide, alone and in combination, in guinea-pig isolated trachea Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis Year: 2015
Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma? Source: Eur Respir Rev 2015; 25: 54-64 Year: 2016